GNPXGenprex, Inc.Signing up patients
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
Carcinoma, Non-Small Cell Lung
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 158 (planned)
- Started
- Sep 3, 2021
- Main results expected
- Mar 2028
- Fully finished
- Mar 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Recommended Phase 2 Dose (RP2D) - Phase 1
Measured over: First 21-day treatment cycle for each dose level cohort
Overall Response Rate (ORR) - Phase 2a
Measured over: Approximately 3 months
Progression-free Survival (PFS) - Phase 2b
Measured over: Approximately 11 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04486833 · record last updated 2026-09-16 · checked 2026-11-09 15:47 UTC